Introduction
============

Malignant tumors are still one of the leading causes of death on a global scale. According to the latest statistics, in 2015, about 589,430 Americans are estimated to die of cancer, or about 1,620 people per day. Cancer is the second most common cause of death in the US, is exceeded only by heart disease, and accounts for nearly one of every four deaths.[@b1-ott-9-5225] Moreover, the death rate of cancer continuously increases due to the lack of early cancer detection such as widespread screening of cancer biomarkers.

Genetic polymorphisms have been widely accepted to play a significant role in human diseases. In recent years, the relationship between genetic polymorphisms and the risk of cancers has been extensively investigated. A large number of recent studies have shown that DNA utility could be regarded as a cancer-related biomarker, which is supported by the finding that some DNA displayed altered expression profiles in cancers compared with matched normal tissues. A large amount of genes, including *betaine-homocysteine methyl-transferase* (*BHMT*), have been confirmed to contribute to the complex molecular mechanisms involved in the control of cell differentiation, growth, and survival processes, which are tightly related to cancer development and progression.

The human *BHMT* gene has been mapped to chromosome 5q13.1-q15,[@b2-ott-9-5225] and a common single nucleotide polymorphism (c.742G\>A; rs3733890), which replaces an arginine by a glutamine at codon 239 (R239Q).[@b3-ott-9-5225] Human *BHMT* gene is supposed to produce an enzyme with higher affinity to homocysteine than the wild type.[@b4-ott-9-5225] This polymorphism possibly plays a critical role in Hcy homeostasis. We have found the approximated frequency of 0.30 for *BHMT* 742G\>A according to the studies.[@b5-ott-9-5225]--[@b10-ott-9-5225] Concretely, the allelic frequencies described in control samples were 0.25--0.33 in the US,[@b5-ott-9-5225] 0.31 in Canada,[@b6-ott-9-5225] 0.28 and 0.29 in Poland,[@b7-ott-9-5225] 0.30 in Romania,[@b8-ott-9-5225] 0.30 in People's Republic of China,[@b9-ott-9-5225] and 0.31 in the Netherlands.[@b10-ott-9-5225]

In 2007, Hazra et al[@b11-ott-9-5225] suggested that the association between *BHMT* polymorphism and cancer for the first time in a study about 24 related gene polymorphisms related to colorectal cancer in the one-carbon metabolic pathway. A subsequent study[@b6-ott-9-5225] has mentioned *BHMT* gene polymorphisms and tumor susceptibility. Moreover, a recent study[@b12-ott-9-5225] that aimed to explore the molecular mechanisms involved in the association between abnormal transcription of *BHMT* and liver cancer risk has indicated a significant reduction in *BHMT* gene expression in HepG2 cells and matched cancerous/adjacent normal liver samples from patients, which provided the explanation for the decreased *BHMT* mRNA levels previously reported in tumor tissue[@b13-ott-9-5225] and the decreased BHMT protein in hepatocellular carcinoma.[@b14-ott-9-5225],[@b15-ott-9-5225] Therefore, we can infer that it has a close relationship between polymorphisms of *BHMT* and other cancer susceptibility, including uterine cervical cancer,[@b16-ott-9-5225] ovarian cancer,[@b17-ott-9-5225] and colorectal adenoma.[@b11-ott-9-5225] These cancer types were taken as candidates to know the associations between *BHMT* polymorphisms and cancer susceptibility. Current individual studies did not have enough efficiency to elaborate their association. Therefore, we conducted the present meta-analysis to derive a more precise result of the relationship between *BHMT* rs3733890 polymorphism and cancer risk by pooling all available data together.

Methods
=======

Literature search strategy
--------------------------

The articles were collected from PubMed, Google Scholar, and CNKI (Chinese). The keywords were (BHMT OR betaine homocysteine methyltransferase) AND (polymorphism OR SNP OR variant OR mutation) AND (cancer OR tumor OR carcinoma OR neoplasm OR malignancy). Meanwhile, we selected the studies that have been published in Chinese or English by December 2015 to determine the correlation by reading titles and abstracts, and read the full text to filter the unqualified articles.

Identification of eligible studies
----------------------------------

We enrolled the studies that met the following criteria: 1) the inclusion of the literature is a case--control study; 2) the data can be extracted from the case group and the control group; 3) the studies provide plenitudinous data for calculating the odds ratio (OR) and the corresponding 95% confidence intervals (95% CI); and 4) detailed genotyping data were recorded in the study.

Quality score evaluation
------------------------

Data were disposed independently by two authors (Y Xu and C Yan). A consensus was finally reached by comprehensively comparing the data, and extensive discussion. Then, the following information from each included study was extracted: first author, publication year, ethnicity, genotyping method, source of control groups, cancer types, and the number of cases and controls.

Statistical analysis and publication bias evaluation
----------------------------------------------------

STATA 12.0 software version (STATA Corp, College Station, TX, USA) was used for statistical analysis. The associations with cancer risk were detected underlying genotyping models, including allele comparision, recessive model, dominant model, homozygote model and heterozygote model. Computation corresponding to OR and 95% CI of the selected case--control studies was employed to evaluate the association between the *BHMT* polymorphism and cancer risk. The publication bias was evaluated by the Egger regression and Begg's funnel plots test. *P*\<0.05 means statistically significant. *P*^a^ means *P*-value of *Q*-test for heterogeneity test. The index is used to evaluate the heterogeneity.

Results
=======

Description of search results
-----------------------------

As shown in [Figure 1](#f1-ott-9-5225){ref-type="fig"}, 24 studies were retrieved initially using the search strategy described in the Methods section. After reading the title or abstract, we excluded 13 irrelevant studies. We further evaluated the remaining eleven potential relevant studies by reading the full-length text. Four studies were excluded due to lack of detailed genotyping data.

Finally, seven articles (including study stages) were selected for meta-analysis. The main characteristics of the seven study stages for the meta-analysis are shown in [Table 1](#t1-ott-9-5225){ref-type="table"}. For *BHMT* rs3733890 polymorphisms, 2,832 cases and 3,958 controls were enrolled in our analysis, the ethnicities consisted of Asian (one study), Caucasian (five studies), and mix (one study). Among the genotyping methods of these studies, three were polymerase chain reaction-restriction fragment length polymorphism, and the others were TaqMan. The sources of control were from hospital, and the types of cancer included head and neck squamous cell carcinoma, breast cancer, uterine cervical carcinoma, and ovarian cancer.

Meta-analysis
-------------

The results of meta-analysis for rs3733890 polymorphism in *BMHT* and cancer susceptibility are shown in [Table 2](#t2-ott-9-5225){ref-type="table"}. According to the results of analysis, we found that the distribution of G742A genotype showed no statistically significant differences in the case and control groups. In the subgroup analyses, performed by ethnicity and genotyping methods, we revealed a negative result ([Table 2](#t2-ott-9-5225){ref-type="table"}).

Meanwhile, from the forest plots, significantly decreased associations were observed in uterine cervical carcinoma regarding *BHMT* −742G\>A polymorphism (A vs G: OR =0.641, 95% CI =0.445--0.923, *P*=0.017; AA+AG vs GG: OR =0.579, 95% CI =0.362--0.924, *P*=0.022) ([Figure 2](#f2-ott-9-5225){ref-type="fig"}). No significant associations were detected in head and neck squamous cell carcinoma, breast cancer, ovarian cancer, colorectal adenoma, and liver cancer regarding *BHMT* −742G\>A polymorphism ([Table S1](#SD1-ott-9-5225){ref-type="supplementary-material"}).

Sensitivity analyses and publication bias
-----------------------------------------

Sensitivity analysis for *BHMT* rs3733890 polymorphism and cancer risk was conducted by removing one individual study a time from the pooled OR ([Figure 3](#f3-ott-9-5225){ref-type="fig"}), whereas the overall statistical significance did not change, indicating that the results are stable.

Begg's funnel plot and Egger's regression were also performed to evaluate the publication bias. The Begg's funnel plot of *BHMT* rs3733890 polymorphism and cancer risk for allelic comparison is shown in [Figure 4](#f4-ott-9-5225){ref-type="fig"}; it seemed symmetrical, indicating the nonexistence of publication bias. Egger's test was used to assess for publication bias. According to Egger's test, we found no evidence of publication bias (A vs G, Egger's *P*=0.573, Begg's *P*=0.764).

Quality assessment
------------------

Generally, it is well established to assess the methodological "quality" of included studies based on the Newcastle--Ottawa scale for quality of case--control studies and cohort studies in meta-analysis. For this assessment, we used the star system (ranged from zero to nine stars) and considered a study awarded five or more stars as a high-quality study.[@b21-ott-9-5225] The values of the seven case--control studies ranged from six stars to eight stars ([Table 3](#t3-ott-9-5225){ref-type="table"}).

Discussion
==========

Over the past decades, the role of polymorphisms in gene encoding enzymes of *BHMT* metabolism has drawn much attention. *BHMT* has been detected in eukaryotes and prokaryotes.[@b22-ott-9-5225]--[@b24-ott-9-5225] Until now, most of the previous studies have been carried out in mammals, and the protein levels could be detected generally at day 10 after gestation or in adults.[@b22-ott-9-5225],[@b25-ott-9-5225] The *BHMT* gene is polymorphic in the nucleotide 742G\>A, with a substitution of arginine for glutamine in the protein.[@b26-ott-9-5225] These polymorphisms are believed to contribute to the risk for liver cancer, although the mechanism by which this may occur is not clearly understood. Plenty of molecular epidemiologic studies have evaluated the role of *BHMT* polymorphism in different cancer. Xu et al[@b6-ott-9-5225] conducted a case--control study, which enrolled 1,065 cases and 1,109 controls. The *BHMT* rs3733890 polymorphism has been reported previously in this population, but it was not associated with breast cancer risk. Then, in order to verify Xu et al's findings, Mostowska et al[@b16-ott-9-5225] conducted a case--control study, which enrolled 142 cases and 168 controls, and they identified that GG and AG genotype of *BHMT* polymorphism had a 1.6- and 1.2-fold increased risk for cervical cancer. In addition, a study that included a total of 762 individuals (272 patients with head and neck cancer and 490 controls), conducted by da Silva et al,[@b18-ott-9-5225] suggests that *BHMT* G742A associated to tobacco increases head and neck squamous cell carcinoma risk. As the result remains controversy in the association between *BHMT* rs3733890 polymorphism and cancer risk, meta-analysis is regarded as a crucial method to accurately define the influence of specific genetic polymorphisms on cancer susceptibility. However, the association between *BHMT* polymorphism and other tumor susceptibility has still not been found. In the stratification analyses for *BHMT* rs3733890 polymorphism by ethnicity, genotyping method or control source, no significant association was observed in the subgroups.

Malignant tumor is a complex multi-gene genetic disease; several factors can cause diverse research results in revealing the possible correlations between cancer risk and gene polymorphisms. Among the influential factors, racial specificity, environmental stress, living habits, and unclear interactions between identified and unidentified genes might play important roles. Particularly, there has been accumulating evidence regarding the joint effects of commonly occurring single nucleotide polymorphisms (SNPs) on cancer risks,[@b27-ott-9-5225]--[@b30-ott-9-5225] supported by polygenic models in various cancer types including breast,[@b31-ott-9-5225] colorectum,[@b32-ott-9-5225] head/neck,[@b33-ott-9-5225] oral cavity,[@b34-ott-9-5225] liver,[@b30-ott-9-5225] cervical,[@b35-ott-9-5225] and ovarian cancer.[@b36-ott-9-5225] Most of these studies have focused on the interactions of genome-wide SNPs, which are located in different chromosomes. Consistent with our findings, most aforementioned studies have addressed that the effects of some SNPs could be categorized as "not associated" and further concluded that they were not important in cancer risks. The possible explanation was that some SNPs might not possess main effects or only possessed negligible effects to interact with other SNPs and subsequently conferred a changed risk for cancers.[@b37-ott-9-5225] Meanwhile, the limited eligible studies may further lead to the lack of statistically significant differences.

The underlying mechanisms of the carcinogenesis are obscure because of the involvement of multiple risk factors containing complicated gene--gene and gene--environment interactions.[@b38-ott-9-5225] Although considerable retrieval and analysis have been done, the following limitations exist. Firstly, the eligible studies were limited and the corresponding sample size was made relatively small. A large sample size and multicenter study is needed to confirm the reliability of our conclusion. Secondly, the impact of the differences in population genetic structure should not be ignored. The site itself is not a lethal site. It is in a linkage disequilibrium with the adjacent real lethal sites in some populations, whereas in other populations, there is no linkage disequilibrium, which determined that the site is associated with tumor susceptibility. Thirdly, we recognize that the possible *BHMT* gene SNP--SNP interaction or jointed effect of SNPs is important to comprehensively investigate their roles in various cancerous initiation and progression, which issues we should not ignore. In this meta-analysis, we have obtained only one qualified *BHMT* gene polymorphism rs3733890; therefore, it is impossible to evaluate the SNP--SNP interaction or jointed effect of SNPs within *BHMT* gene polymorphisms themselves. In contrast, a previous study[@b20-ott-9-5225] has explored the possible joint effects among the 20 critical candidate genes (*MTHFR*, *TS*, *MTR*, *MTRR*, *MTHRDI*, *PEMT*, *CHDH*, *BHMT*, *SHMTI*, *CHKA*, *SLC19AI*, *TCNZ*, *FOLRI*, *HCPI*, *GNMT*, *DPYD*, *ABCB4*, *DNMTI*, *CBS*, and *DHFR*) involved in the one-carbon metabolism network, which is regarded as an important role on DNA synthesis. Methylation linked the genetic and epigenetic progression closely associated with the development and prevention of several malignancies, and eventually it was found that no positive or meaningful SNP--SNP interactions were associated with *BHMT* gene polymorphisms. However, based on the aforementioned results, we still cannot exclude the possibility that there will be novel SNPs, which could interact with *BHMT* rs3733890. Therefore, we will continue to focus on the progress of the related research studies and make the necessary update. Besides, other external causes, such as individual persons usually have different genetic backgrounds, the differences of the external environment and the susceptibility genes were important influential factors in the current study.

Conclusion
==========

Our study showed that there was no statistically significant association between G742A *BHMT* gene polymorphism and the susceptibility of various cancer types including head and neck squamous cell carcinoma, breast cancer, ovarian cancer, colorectal adenoma, and liver cancer. In contrast, we found the protective role of *BHMT* −742G\>A polymorphism in uterine cervical cancer incidence (A vs G: OR =0.641, 95% CI =0.445--0.923, *P*=0.017; AA+AG vs GG: OR =0.579, 95% CI =0.362--0.924, *P*=0.022). In the future, well-designed studies comprising larger sample size are warranted to further verify these findings.

Supplementary material
======================

###### 

The association between *BHMT* rs3733890 polymorphism and cancer susceptibility in subgroup meta-analysis of cancer types

  Polymorphism   Comparison    Subgroup   N   *P*-value   Regression model                                  
  -------------- ------------- ---------- --- ----------- ------------------ ------- ---------------------- ----------------------
  rs3733890      A vs G        Total      7   0.305       0.830              0.911   0.992 (0.915--1.076)   0.992 (0.924--1.066)
                               HNSCC      1   --          0.544              --      1.071 (0.859--1.335)   1.071 (0.859--1.335)
                               BC         2   0.765       0.789              --      0.985 (0.880--1.102)   0.985 (0.880--1.102)
                               UCC        1   --          **0.017**          --      0.641 (0.445--0.923)   0.641 (0.445--0.923)
                               OC         1   --          0.934              --      1.015 (0.721--1.427)   1.015 (0.721--1.427)
                               CRA        1   --          0.346              --      1.093 (0.909--1.315)   1.093 (0.909--1.315)
                               LC         1   --          0.780              --      0.980 (0.852--1.127)   0.980 (0.852--1.127)
                 AA vs GG      Total      7   0.203       0.878              0.706   1.026 (0.837--1.258)   1.013 (0.863--1.188)
                               HNSCC      1   --          0.318              --      1.279 (0.789--2.073)   1.279 (0.789--2.073)
                               BC         2   0.986       0.519              --      0.921 (0.717--1.183)   0.921 (0.717--1.183)
                               UCC        1   --          0.065              --      0.433 (0.178--1.054)   0.433 (0.178--1.054)
                               OC         1   --          0.340              --      1.416 (0.693--2.894)   1.416 (0.693--2.894)
                               CRA        1   --          0.104              --      1.442 (0.928--2.242)   1.442 (0.928--2.242)
                               LC         1   --          0.678              --      0.935 (0.682--1.282)   0.935 (0.682--1.282)
                 AG vs GG      Total      7   0.099       0.799              0.785   0.980 (0.839--1.145)   0.994 (0.894--1.104)
                               HNSCC      1   --          0.750              --      0.950 (0.692--1.304)   0.950 (0.692--1.304)
                               BC         2   0.554       0.658              --      1.036 (0.886--1.212)   1.036 (0.886--1.212)
                               UCC        1   --          0.052              --      0.614 (0.376--1.005)   0.614 (0.376--1.005)
                               OC         1   --          0.088              --      0.647 (0.393--1.067)   0.647 (0.393--1.067)
                               CRA        1   --          0.067              --      1.514 (0.972--2.360)   1.514 (0.972--2.360)
                               LC         1   --          0.954              --      1.006 (0.827--1.224)   1.006 (0.827--1.224)
                 AA+AG vs GG   Total      7   0.135       0.840              0.924   0.984 (0.855--1.132)   0.990 (0.896--1.093)
                               HNSCC      1   --          0.947              --      1.010 (0.749--1.363)   1.010 (0.749--1.363)
                               BC         2   --          0.880              --      1.011 (0.872--1.173)   1.011 (0.872--1.173)
                               UCC        1   --          **0.022**          --      0.579 (0.362--0.924)   0.579 (0.362--0.924)
                               OC         1   --          0.312              --      0.788 (0.496--1.251)   0.788 (0.496--1.251)
                               CRA        1   --          0.071              --      1.313 (0.833--2.070)   1.313 (0.833--2.070)
                               LC         1   --          0.929              --      0.992 (0.823--1.195)   0.992 (0.823--1.195)
                 AA vs AG+GG   Total      7   0.334       0.895              0.572   0.995 (0.855--1.157)   0.991 (0.865--1.135)
                               HNSCC      1   --          0.241              --      1.313 (0.833--2.070)   1.313 (0.833--2.070)
                               BC         2   0.867       0.416              --      0.905 (0.713--1.150)   0.906 (0.713--1.150)
                               UCC        1   --          0.162              --      0.541 (0.229--1.279)   0.541 (0.229--1.279)
                               OC         1   --          0.106              --      1.743 (0.888--3.420)   1.743 (0.888--3.420)
                               CRA        1   --          0.853              --      1.023 (0.803--1.304)   1.023 (0.803--1.304)
                               LC         1   --          0.649              --      0.933 (0.691--1.259)   0.933 (0.691--1.259)

**Note:** The values shown in bold indicate that when *P*\<0.05, the association between *BHMT* rs3733890 polymorphism and cancer risk could be regarded as statistically significant.

**Abbreviations:** BC, breast cancer; CRA, colorectal adenoma; HNSCC, head and neck squamous cell carcinoma; LC, liver cancer; OC, ovarian cancer; UCC, uterine cervical carcinoma; PH, *P*-value for heterogeneity test; PZ, *P*-value for *Z* test (significance test); PE, *P*-value for Egger's test.
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![Flow diagram of the inclusion and exclusion of studies in this meta-analysis.](ott-9-5225Fig1){#f1-ott-9-5225}

![Forest plots describing the meta-analysis for the association between the *BHMT* rs373389 polymorphism and cancer risk.\
**Notes:** (**A**) Allele contrast (A vs G) and (**B**) dominant model (AA+AG vs GG). Each square indicates a study, and the area of the squares is proportional to the weight of the study. The diamond represents the summary OR, and the transverse line means 95% CI.\
**Abbreviations:** CI, confidence interval; OR, odds ratio.](ott-9-5225Fig2){#f2-ott-9-5225}

![Sensitivity analysis of *BHMT* rs3733890 polymorphism in allelic comparison (A vs G).\
**Notes:** The middle vertical solid line is the estimated line. The left-most line is the lower CI limit. The right-most line is the upper CI limit. Each circle is a separate study and indicates OR. The dotted line means 95% CI.\
**Abbreviations:** CI, confidence interval; OR, odds ratio.](ott-9-5225Fig3){#f3-ott-9-5225}

![Begg's funnel plot for publication bias test of *BHMT* rs3733890 polymorphism in allelic comparison (A vs G).\
**Notes:** The *x*-axis is log (OR) and the *y*-axis is natural logarithm of OR. The horizontal line in the figure means the overall estimated log (OR). The two diagonal lines indicate the pseudo 95% confidence limits of the effect estimate.\
**Abbreviations:** OR, odds ratio; log (OR), log-transformed OR; SE, standard error.](ott-9-5225Fig4){#f4-ott-9-5225}

###### 

Main characteristics of studies regarding the association between *BHMT* gene rs3733890 polymorphism and cancer risk

  SNP         Authors                            Year   Ethnicity   Genotyping method   Source of control   Cancer type   Cases   Controls                     
  ----------- ---------------------------------- ------ ----------- ------------------- ------------------- ------------- ------- ---------- ----- ----- ----- -----
  rs3733890   de Silva et al[@b18-ott-9-5225]    2012   Mix         PCR-RFLP            PB                  HNSCC         117     119        36    212   227   51
              Xu et al[@b6-ott-9-5225]           2008   Caucasian   TaqMan              CB                  BC            510     443        108   530   456   122
              Mostowska et al[@b16-ott-9-5225]   2011   Caucasian   PCR-RFLP            HB                  UCC           70      46         8     72    77    19
              Pawlik et al[@b17-ott-9-5225]      2012   Caucasian   PCR-RFLP            HB                  OC            64      47         23    67    76    17
              Hazra et al[@b11-ott-9-5225]       2007   Caucasian   TaqMan              HB                  CRA           40      237        248   57    223   245
              Xu et al[@b19-ott-9-5225]          2008   Caucasian   TaqMan              PB                  BC            192     183        43    128   108   31
              An[@b20-ott-9-5225]                2008   Asian       TaqMan              PB                  LC            315     310        73    557   545   138

**Abbreviations:** BC, breast cancer; CB, community-based; CRA, colorectal adenoma; HB, hospital-based; HNSCC, head and neck squamous cell carcinoma; LC, liver cancer; OC, ovarian cancer; PB, population-based; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; SNP, single nucleotide polymorphism; UCC, uterine cervical carcinoma.

###### 

Results of meta-analysis for the association between *BMHT* gene polymorphism and cancer susceptibility

  Variables (rs3733890)   Case/control   A vs G                 AA vs GG   AG vs GG                                                                        
  ----------------------- -------------- ---------------------- ---------- ---------- ---------------------- ------- ------ ---------------------- ------- ------
  Total                   2,832/3,958    0.992 (0.924--1.066)   0.305      16.4       1.013 (0.863--1.188)   0.203   29.6   0.980 (0.839--1.145)   0.099   43.8
  Genotyping method                                                                                                                                        
   PCR-RFLP               530/818        0.950 (0.806--1.120)   0.057      65.2       1.077 (0.752--1.542)   0.079   60.7   0.765 (0.569--1.028)   0.233   31.4
   TaqMan                 2,302/3,140    1.002 (0.926--1.085)   0.771      0.0        0.997 (0.835--1.192)   0.357   7.3    1.056 (0.933--1.195)   0.365   5.6
  Ethnicity                                                                                                                                                
   Caucasian                             0.985 (0.901--1.077)   0.155      40.0       1.005 (0.822--1.229)   0.117   45.8   0.961 (0.740--1.248)   0.032   62.2
   Asian                                 0.980 (0.852--1.127)                         0.935 (0.682--1.282)                  1.006 (0.827--1.224)           
   Mix                                   1.071 (0.859--1.335)                         1.279 (0.789--2.073)                  0.950 (0.692--1.304)           
                                                                                                                                                           
                                         **AA+AG vs GG**                              **AA vs AG+GG**                                                      
                                                                                                                                                           
  Total                   2,832/3,958    0.990 (0.896--1.093)   0.135      38.5       0.991 (0.865--1.135)   0.334   12.6                                  
  Genotyping method                                                                                                                                        
   PCR-RFLP               530/818        0.842 (0.676--1.050)   0.138      49.6       1.210 (0.861--1.700)   0.100   56.6                                  
   TaqMan                 2,302/3,140    1.031 (0.923--1.153)   0.355      7.6        0.955 (0.823--1.107)   0.907   0.0                                   
  Ethnicity                                                                                                                                                
   Caucasian                             0.985 (0.867--1.120)   0.045      58.9       0.974 (0.829--1.145)   0.267   23.1                                  
   Asian                                 0.992 (0.823--1.195)                         0.933 (0.691--1.259)                                                 
   Mix                                   1.010 (0.749--1.363)                         1.313 (0.833--2.070)                                                 

**Notes:** *I*^2^ (%): 0--25, no heterogeneity; 25--50, modest heterogeneity; \>50, high heterogeneity;

*P*-value of *Q*-test for heterogeneity test.

**Abbreviations:** CI, confidence interval; OR, odds ratio; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism.

###### 

Methodological quality of the included studies according to the Newcastle-Ottawa scale

  SNP                Authors                            Ethnicity   Adequacy of case definition   Representativeness of the cases   Selection of controls   Definition of controls   Comparability cases/controls   Ascertainment of exposure   Same method of ascertainment   Nonresponse rate
  ------------------ ---------------------------------- ----------- ----------------------------- --------------------------------- ----------------------- ------------------------ ------------------------------ --------------------------- ------------------------------ ------------------
  *BHMT* rs3733890   da Silva et al[@b18-ott-9-5225]    Mix         ^\*^                          NA                                NA                      ^\*^                     ^\*\*^                         ^\*^                        ^\*^                           ^\*^
                     Xu et al[@b6-ott-9-5225]           Caucasian   ^\*^                          ^\*^                              NA                      NA                       ^\*\*^                         ^\*^                        ^\*^                           ^\*^
                     Mostowska et al[@b16-ott-9-5225]   Caucasian   ^\*^                          ^\*^                              NA                      ^\*^                     ^\*\*^                         ^\*^                        ^\*^                           ^\*^
                     Pawlik et al[@b17-ott-9-5225]      Caucasian   ^\*^                          ^\*^                              NA                      ^\*^                     ^\*^                           ^\*^                        ^\*^                           ^\*^
                     Hazra et al[@b11-ott-9-5225]       Caucasian   ^\*^                          ^\*^                              NA                      ^\*^                     ^\*\*^                         ^\*^                        ^\*^                           ^\*^
                     Xu et al[@b19-ott-9-5225]          Caucasian   ^\*^                          ^\*^                              NA                      ^\*^                     ^\*\*^                         ^\*^                        ^\*^                           ^\*^
                     An[@b20-ott-9-5225]                Asian       NA                            NA                                NA                      ^\*^                     ^\*\*^                         ^\*^                        ^\*^                           ^\*^

**Notes:** Risk of bias was assessed using the Newcastle-Ottawa scale. A higher overall score corresponds to a lower risk of bias; a score of 5 (out of 9) indicates a high risk of bias. This table identifies "high-quality" choices with \*. A study can be awarded a maximum of one asterisk for each numbered item within the selection and exposure categories. A maximum of two asterisks can be given for comparability.

**Abbreviations:** NA, not available; SNP, single nucleotide polymorphism.
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